G

Geron Corp
D

GERN

2.99500
USD
0.04
(1.18%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
-9
حجم السوق
1,810,480,543
أصول ذات صلة
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    JNJ
    JNJ
    -2.915
    (-1.97%)
    145.250 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    PFE
    PFE
    -0.621
    (-2.33%)
    26.015 USD
    T
    TK
    -0.10000
    (-1.42%)
    6.94000 USD
    V
    VSTM
    0.12500
    (2.32%)
    5.51000 USD
    XOM
    XOM
    -1.960
    (-1.76%)
    109.530 USD
    المزيد
الأخبار المقالات

العنوان: Geron Corp

القطاع: Healthcare
الصناعة: Biotechnology
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.